| Identification | Back Directory | [Name]
3-Hydrazino-6-((2-hydroxypropyl)methylamino)pyridazine dihydrochloride | [CAS]
64000-73-3 | [Synonyms]
Propyldazine
propildazine
1-[(6-Hydrazino-3-pyridazinyl)(methyl)amino]-2-propanol
2-Propanol, 1-[(6-hydrazinyl-3-pyridazinyl)methylamino]-
1-[(6-hydrazino-pyridazin-3-yl)-methyl-amino]-propan-2-ol
6-[(2-Hydroxypropyl)methylamino]-3(2H)-pyridazinone hydrazone
3-Hydrazino-6-((2-hydroxypropyl)methylamino)pyridazine dihydrochloride | [Molecular Formula]
C8H15N5O | [MDL Number]
MFCD00865910 | [MOL File]
64000-73-3.mol | [Molecular Weight]
197.24 |
| Hazard Information | Back Directory | [Uses]
Pildralazine (Propyldazine) is a hydralazinelike antihypertensive vasodilator containing a free hydrazine group. Pildralazine is orally active, has no significant carcinogenicity in mice model[1][2]. | [Definition]
ChEBI: Pildralazine is a tertiary amino compound and a dialkylarylamine. | [in vivo]
Pildralazine (6-43 mg/kg; p.o.; once daily) shows no significant carcinogenicity in B6C3F1 and BALB/c mice under a long-term bioassay and a transplacental-infantile bioassay[1].
Pildralazine and Hydralazine.html" class="link-product" target="_blank">Hydralazine (HY-B0464A) act on a common receptor,sensitive to endogenous ATP and adenosine in the isolated tail artery from normotensive Wistar (NW) rats[2].
Pildralazine (1 mg/kg; p.o.; ) significantly inhibits the onset of severe hypertension in spontaneously hypertensive rats (SHR) model[3].
| Animal Model: | Male and female B6C3F1 and to female BALB/c mice (8 weeks old)[1] | | Dosage: | 100, 200, and 400 ppm dose: 8, 20, and 40 mg/kg/day in B6C3F1 males, 8, 22, and 43 mg/kg/day in B6C3F1 females, and 6, 15, and 34 mg/kg/day in BALB/c females, respectively | | Administration: | Oral gavage; added in the drinking water; provided for 80 weeks, and observed for 130-133 weeks age | | Result: | Resulted over 80% of mice alive beyond 78 weeks of age. |
| [References]
[1] Della Porta G, Dragani TA. Carcinogenicity study in mice on pildralazine, a hydralazinelike antihypertensive compound. J Cancer Res Clin Oncol. 1983;106(2):97-101. DOI:10.1007/BF00395386
[2] Chevillard C, et al. Interactions between hydralazine, propildazine and purines on arterial smooth muscle. Br J Pharmacol. 1981 Aug;73(4):811-7. DOI:10.1111/j.1476-5381.1981.tb08733.x
[3] Dorigotti L, et al. Effects of pildralazine alone and in combination on severe hypertension and cerebrovascular lesions in saline-drinking spontaneously hypertensive rats. Arzneimittelforschung. 1984;34(8):876-9. PMID:6541924 |
|
|